146
Participants
Start Date
December 27, 2018
Primary Completion Date
July 5, 2022
Study Completion Date
July 5, 2022
AR101 powder provided in capsules & sachets
Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Placebo powder provided in capsules & sachets
Study product formulated to contain only inactive ingredients for use as defined in the protocol
Icahn School of Medicine at Mount Sinai, New York
Charité Universitaetsmedizin Berlin, Berlin
The John Hopkins Hospital, Baltimore
UNC-CH School of Medicine, Pediatric Allergy, Immunology & Rheumatology, Food Allergy, Chapel Hill
Clinical Research of Charlotte, Charlotte
Atlanta Allergy & Asthma Clinic, Marietta
Children's Center for Advanced Pediatrics Clinical Research Lab, Atlanta
University of Michigan Division of Allergy and Clinical Immunology, Ann Arbor
University of Frankfurt, Frankfurt am Main
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Arkansas Children's Hospital, Little Rock
Peninsula Research Associates, Inc., Rolling Hills Estates
Allergy & Asthma Medical Group and Research Center, San Diego
Sean N. Parker Center for Allergy & Asthma Reseach, LPCH at El Camino Hospital, Mountain View
Virginia Mason Medical Center, Seattle
Atlantic Research Center, Ocean City
Jeanne de Flandre Hospital, Lille
James Paget University Hospital, Gorleston-on-Sea
Leicester Royal Infirmary, Leicester
Guy's and St. Thomas' NHS Foundation Trust, Snowy Owl, First Floor, Evelina Children's Hospital, London
Royal Manchester Children's Hospital Central Manchester University Hospitals, Manchester
Sheffield Children's Hospital, Sheffield
University Hospital Southampton Foundation NHS Trust Southampton General Hospital, Southampton
Lead Sponsor
Aimmune Therapeutics, Inc.
INDUSTRY